Team:EPF-Lausanne/Playground

From 2011.igem.org

(Difference between revisions)
 
(4 intermediate revisions not shown)
Line 1: Line 1:
{{:Team:EPF-Lausanne/Templates/Header|title=Playground}}
{{:Team:EPF-Lausanne/Templates/Header|title=Playground}}
-
We have developed a pipeline for selection and characterization of novel transcription factors, specifically:
+
<html><img src="https://static.igem.org/mediawiki/2010/b/b0/UCL-Igem.png" alt="iGEM Logo" width="200px" style="float:right"/></html>
 +
 
 +
We have developed a pipeline for selection and characterization of new transcription factors, specifically:
# ''in vivo'' selection of functional mutants from a large library of variants using a “survival of the weakest” strategy,
# ''in vivo'' selection of functional mutants from a large library of variants using a “survival of the weakest” strategy,
Line 11: Line 13:
<html>
<html>
<div class="frontpagebox odd">
<div class="frontpagebox odd">
-
<h2><i>In vitro</i> TF selection system</h2>
+
<h2><i>In vivo</i> TF selection system</h2>
<p>As the first step in our pipeline we propose a new in vivo method for the automated selection of mutant transcription factors or transcription factor binding sites from large and diverse libraries containing millions of variants. The novelty of our approach lies in the fact that we use negative selection, or “survival of the weakest” as the selection strategy. In our method, a functional variant activates lysis of the host, leading to release of the plasmid DNA coding for the functional variant. The plasmid DNA can then be amplified, transformed, or directly sequenced to determine which variants were functional. We believe that our negative selection scheme is a potentially powerful approach when coupled to next-generation sequencing. Using a proof-of-concept version of the system, consisting of a T7 driven lysis cassette we were able to show that:<p>  
<p>As the first step in our pipeline we propose a new in vivo method for the automated selection of mutant transcription factors or transcription factor binding sites from large and diverse libraries containing millions of variants. The novelty of our approach lies in the fact that we use negative selection, or “survival of the weakest” as the selection strategy. In our method, a functional variant activates lysis of the host, leading to release of the plasmid DNA coding for the functional variant. The plasmid DNA can then be amplified, transformed, or directly sequenced to determine which variants were functional. We believe that our negative selection scheme is a potentially powerful approach when coupled to next-generation sequencing. Using a proof-of-concept version of the system, consisting of a T7 driven lysis cassette we were able to show that:<p>  
Line 37: Line 39:
<p>We noticed that only a small number of iGEM teams have also made use of microfluidics in the past. Because we think that microfluidics is a useful tool for the iGEM community, we decided to promote the technique by creating the [http://tamagotchip.epfl.ch tamagotchip] live online microfluidics game: from any web browser, you can control the setup located in our lab in Lausanne, as detailed <a href="/Team:EPF-Lausanne/Tools/Microfluidics/Tamagotchip">here</a>. In addition, we wrote a <a href="Team:EPF-Lausanne/Tools/Microfluidics">guide on the wiki</a> to help future teams get started with these techniques.</p>
<p>We noticed that only a small number of iGEM teams have also made use of microfluidics in the past. Because we think that microfluidics is a useful tool for the iGEM community, we decided to promote the technique by creating the [http://tamagotchip.epfl.ch tamagotchip] live online microfluidics game: from any web browser, you can control the setup located in our lab in Lausanne, as detailed <a href="/Team:EPF-Lausanne/Tools/Microfluidics/Tamagotchip">here</a>. In addition, we wrote a <a href="Team:EPF-Lausanne/Tools/Microfluidics">guide on the wiki</a> to help future teams get started with these techniques.</p>
 +
</div>
</html>
</html>
 +
 +
In summary, over the summer we:
 +
* developed and characterized a new in vivo selection system based on “survival of the weakest”.
 +
* created and characterized a set of T7 promoter variants that express with different strengths.
 +
* created several TetR variants.
 +
* created several reporter systems for the in vivo characterization of TetR.
 +
* determined the binding energy landscape of TetR and a number of TetR mutants using MITOMI.
 +
* developed a cheap and easy to build a microfluidic setup for the iGEM community
{{:Team:EPF-Lausanne/Templates/Footer}}
{{:Team:EPF-Lausanne/Templates/Footer}}

Latest revision as of 23:14, 20 September 2011